# Targeting Metabolic Liabilities in Cancer

> **NIH NIH R01** · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2021 · $390,657

## Abstract

Summary/Abstract
 In transformed cells the demand to accumulate biomass requires substantial metabolic pathway alteration.
Understanding this altered metabolism will enable identification of liabilities that can be exploited for cancer
therapy. In prior work, we found that hyperoxic stress is a considerable force driving metabolic pathway
dependence in breast cancer. Indeed, the enzyme most differentially required in high versus low oxygen
environments, NFS1, is required for breast cancer metastasis to the lung. Moreover, NFS1 lies in an amplified
region under positive selection in lung adenocarcinoma. Therefore, from prior work we conclude that the high
oxygen environment of the lung is a key metabolic factor to which incipient breast metastases and lung tumors
uniquely adapt, in part, via NFS1. Ours is the first work to describe a role for this critical pathway in cancer.
 The purpose of this grant is to gain mechanistic understanding of the NFS1 requirement, focusing on basal-
like breast cancer (BLBC). NFS1 is a key enzyme in the biosynthesis of iron-sulfur clusters (ISC), essential
cofactors in 48 proteins in humans. We found that BLBC cell lines are strikingly more sensitive than luminal
lines to suppression of NFS1. We propose to identify the mechanistic underpinnings of this observation, and
extend our findings to other cancer subtypes. We will suppress ISC containing proteins in a panel of breast
cancer cell lines and verify which are differentially required in BLBC. Validated targets will be inhibited in
xenograft-based models of breast cancer and metastasis to assess their impact on these processes.
 Many ISC containing genes are involved in the maintenance of genomic integrity. Our preliminary work
reveals that NFS1 suppression results in the formation of double strand DNA breaks. These observations led
us to suppress POLE, a key genomic integrity enzyme. Interestingly, suppression of POLE also blocks
proliferation and induces double strand breaks in BLBC cell lines far more than luminal lines. Prior work has
indicated that BLBC has defects in aspects of DNA repair that may sensitize them to therapy. Therefore we will
suppress POLE and assess the impact on DNA replication, origin firing, replication fork stalling and restarting,
and the repair of damaged replication forks. These experiments will contribute to our fundamental
understanding of the sensitivity of BLBC to inhibition of DNA replication and induction of DNA damage.
 Finally, NFS1 suppression sensitizes cells to oxidative damage via a non-apoptotic form of cell death
termed ferroptosis. Our findings lead to the intriguing possibility that activation of the iron-starvation response
in iron-replete conditions, thereby tricking cancer cells into taking up excess iron, will render them highly
susceptible to further oxidative stress and death by ferroptosis. By mechanistically understanding how best to
activate the iron-starvation response downstream of NFS1, we anticipate that w...

## Key facts

- **NIH application ID:** 10079472
- **Project number:** 5R01CA214948-04
- **Recipient organization:** NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- **Principal Investigator:** Richard Lewis Possemato
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $390,657
- **Award type:** 5
- **Project period:** 2018-02-01 → 2023-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10079472

## Citation

> US National Institutes of Health, RePORTER application 10079472, Targeting Metabolic Liabilities in Cancer (5R01CA214948-04). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10079472. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
